| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI0215595 |
| 10.1172/JCI15595 | ||
| P3181 | OpenCitations bibliographic resource ID | 1847189 |
| P932 | PMC publication ID | 151031 |
| P698 | PubMed publication ID | 12093887 |
| P50 | author | Daniel J. Drucker | Q19966099 |
| P2093 | author name string | Charlotte E. Lee | |
| Joel K. Elmquist | |||
| Hiroshi Yamamoto | |||
| Clifford B. Saper | |||
| Anthony N. Hollenberg | |||
| Todd D. Williams | |||
| J. Michael Overton | |||
| Jacob N. Marcus | |||
| Laurie Baggio | |||
| Marisol E. Lopez | |||
| P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
| A5 noradrenergic unit activity and sympathetic nerve discharge in rats | Q30447505 | ||
| Autonomic nervous system control of heart rate during baroreceptor activation in conscious and anesthetized rats | Q30463149 | ||
| Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation | Q32160952 | ||
| Circuits and mechanisms governing hypothalamic responses to stress: a tale of two paradigms | Q33875313 | ||
| Sequence of stress-induced alterations in indices of synaptic and transcriptional activation in parvocellular neurosecretory neurons | Q34062464 | ||
| The entero-insular axis in type 2 diabetes--incretins as therapeutic agents | Q34312081 | ||
| Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). | Q38324621 | ||
| Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats | Q38348700 | ||
| The C1 area of the rostral ventrolateral medulla oblongata. A critical brainstem region for control of resting and reflex integration of arterial pressure. | Q38368705 | ||
| Sympathoexcitatory neurons of the rostroventrolateral medulla and the origin of the sympathetic vasomotor tone. | Q38545906 | ||
| Direct hypothalamo-autonomic connections | Q39407341 | ||
| Lipopolysaccharide activates specific populations of hypothalamic and brainstem neurons that project to the spinal cord. | Q40616013 | ||
| Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. | Q40663467 | ||
| Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration | Q40666056 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. | Q41718186 | ||
| Glucagon-like peptides | Q41728544 | ||
| Spatially and temporally differentiated patterns of c-fos expression in brainstem catecholaminergic cell groups induced by cardiovascular challenges in the rat. | Q42280604 | ||
| Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. | Q42445138 | ||
| Neurochemical organization of the hypothalamic projection to the spinal cord in the rat. | Q43550963 | ||
| Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers | Q43638669 | ||
| The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes | Q43913927 | ||
| Organization and evolution of the rat tyrosine hydroxylase gene | Q44799054 | ||
| Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. | Q45937487 | ||
| Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus | Q48138420 | ||
| A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. | Q48177060 | ||
| Descending noradrenergic pathways involved in the A5 depressor response | Q48286516 | ||
| Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system | Q48306367 | ||
| Leptin activates hypothalamic CART neurons projecting to the spinal cord. | Q48308908 | ||
| Rostral ventrolateral medulla: selective projections to the thoracic autonomic cell column from the region containing C1 adrenaline neurons | Q48622841 | ||
| In SituHybridization Analysis of Arginine Vasopressin Gene Transcription Using Intron-Specific Probes | Q48647440 | ||
| Differential expression of orexin receptors 1 and 2 in the rat brain | Q48693654 | ||
| Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem | Q48794136 | ||
| Cardiovascular responses elicited by chemical stimulation of the rostral ventrolateral medulla in conscious, unrestrained rats | Q48854197 | ||
| Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain | Q48905526 | ||
| Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat | Q50935490 | ||
| Concurrent reductions in blood pressure and metabolic rate during fasting in the unrestrained SHR. | Q51558728 | ||
| Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. | Q51562589 | ||
| Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I | Q58012594 | ||
| Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats | Q59616303 | ||
| Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats | Q59616311 | ||
| A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia | Q60302592 | ||
| Direct projections from the A5 catecholamine cell group to the intermediolateral cell column | Q66939887 | ||
| Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study | Q68415323 | ||
| A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections | Q69373002 | ||
| Preganglionic nerve stimulation increases mRNA levels for tyrosine hydroxylase in the rat superior cervical ganglion | Q69375850 | ||
| Hemodynamic regulation of tyrosine hydroxylase messenger RNA in medullary catecholamine neurons: a c-fos-guided hybridization histochemical study | Q71525174 | ||
| Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats | Q73195050 | ||
| Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat | Q74248446 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 43–52 | |
| P577 | publication date | 2002-07-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons | |
| P478 | volume | 110 |
| Q36964030 | A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-cell survival and function. |
| Q46896376 | A possible role of GLP-1 in the pathophysiology of early dumping syndrome |
| Q58447525 | Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow |
| Q48722095 | Activation of Nesfatin-1-Containing Neurones in the Hypothalamus and Brainstem by Peripheral Administration of Anorectic Hormones and Suppression of Feeding via Central Nesfatin-1 in Rats |
| Q30352488 | Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. |
| Q38639922 | An overview of new GLP-1 receptor agonists for type 2 diabetes |
| Q36807579 | Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake |
| Q38200704 | At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose |
| Q88231370 | Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure |
| Q36735857 | Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats |
| Q35180081 | Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice |
| Q36935346 | Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism |
| Q87657519 | Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07 |
| Q35210037 | Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits |
| Q28589384 | Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ |
| Q49027654 | Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. |
| Q40035788 | Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage |
| Q36906298 | Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity |
| Q47255372 | Brain metabolic sensing and metabolic signaling at the level of an astrocyte. |
| Q37174896 | CNS GLP-1 regulation of peripheral glucose homeostasis |
| Q44516249 | CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. |
| Q38767511 | Cardiometabolic crosstalk in obesity-associated arterial hypertension |
| Q38199984 | Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. |
| Q33993725 | Cardiovascular and hemodynamic effects of glucagon-like peptide-1. |
| Q36484283 | Cardiovascular biology of the incretin system |
| Q38026918 | Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? |
| Q26866958 | Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies |
| Q37977336 | Cardiovascular effects of incretin-based therapies |
| Q36796571 | Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation |
| Q90183205 | Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats |
| Q51041822 | Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. |
| Q36211439 | Class II G protein-coupled receptors and their ligands in neuronal function and protection |
| Q37212333 | Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides |
| Q47385994 | Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats |
| Q64267307 | DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs |
| Q48229830 | DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics. |
| Q37429168 | Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats |
| Q35026385 | Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q47868205 | Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity |
| Q37558852 | Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress. |
| Q44472346 | Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes |
| Q34499374 | Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain |
| Q37106861 | Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei |
| Q47252691 | Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults? |
| Q90588144 | Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS |
| Q34269632 | Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome |
| Q39413684 | Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats |
| Q39905736 | Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study |
| Q89688849 | Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men |
| Q36307536 | Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study |
| Q53215510 | Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. |
| Q36882784 | Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans |
| Q53886146 | Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. |
| Q36877627 | Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans |
| Q37951097 | Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension |
| Q51368060 | Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. |
| Q31170579 | Effects of meal and incretins in the regulation of splanchnic blood flow |
| Q48109404 | Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. |
| Q42176063 | Elevated blood pressure, heart rate and body temperature in mice lacking the XLαs protein of the Gnas locus is due to increased sympathetic tone |
| Q37395298 | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? |
| Q34614609 | Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. |
| Q41907589 | Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition |
| Q39220482 | Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males |
| Q64230442 | Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System |
| Q41852482 | Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3. |
| Q35948898 | Exendin-4 decreases amphetamine-induced locomotor activity |
| Q33840311 | Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system |
| Q36895565 | Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts |
| Q98778907 | Exendin-4 inhibits atrial arrhythmogenesis in a model of myocardial infarction-induced heart failure via the GLP-1 receptor signaling pathway |
| Q39253744 | Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway |
| Q35132702 | Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix |
| Q48725317 | Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs |
| Q48087886 | Experimental dissociation of neural circuits underlying conditioned avoidance and hypophagic responses to lithium chloride |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q34252656 | Expression of the diabetes-associated gene TCF7L2 in adult mouse brain |
| Q38065321 | Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes |
| Q90051591 | GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats |
| Q30411123 | GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles |
| Q38709406 | GLP-1 Agonists and Blood Pressure: A Review of the Evidence. |
| Q37885717 | GLP-1 and energy balance: an integrated model of short-term and long-term control |
| Q34336097 | GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure |
| Q38122396 | GLP-1 receptor agonists: effects on cardiovascular risk reduction |
| Q30497661 | GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. |
| Q27000749 | GLP-1, the gut-brain, and brain-periphery axes |
| Q38238288 | GLP-1: benefits beyond pancreas. |
| Q38207948 | GLP-1R activation for the treatment of stroke: updating and future perspectives |
| Q41984767 | GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice |
| Q47153467 | Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39). |
| Q24669951 | Gastrointestinal hormones regulating appetite |
| Q37047199 | Gastrointestinal peptides controlling body weight homeostasis. |
| Q35251043 | Gastrointestinal regulation of food intake |
| Q39164330 | Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure |
| Q34800168 | Gene-environment interactions controlling energy and glucose homeostasis and the developmental origins of obesity |
| Q37800569 | Glucagon-like peptide 1 and the brain: Central actions–central sources? |
| Q45061870 | Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q44512663 | Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium |
| Q34653078 | Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. |
| Q36980756 | Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection |
| Q38033468 | Glucagon-like peptide-1 and its cardiovascular effects |
| Q46278128 | Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication |
| Q37224352 | Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats. |
| Q28570190 | Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression |
| Q35601526 | Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake |
| Q38099388 | Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. |
| Q37825946 | Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. |
| Q40657491 | Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. |
| Q36902266 | Glucosensing in the gastrointestinal tract: Impact on glucose metabolism |
| Q36452530 | Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism |
| Q40173291 | Healthy lifestyle and glucagon-like peptide-1 in young and healthy adults: A population-based study |
| Q38171215 | Heart failure and loss of metabolic control |
| Q61851313 | Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study |
| Q37353922 | Hindbrain cocaine- and amphetamine-regulated transcript induces hypothermia mediated by GLP-1 receptors |
| Q46477363 | Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides |
| Q37892968 | Hypothalamic control of energy and glucose metabolism |
| Q42736812 | Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q42627337 | Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure |
| Q48486475 | Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter |
| Q37845218 | Is the GLP-1 system a viable therapeutic target for weight reduction? |
| Q33621147 | Leptin and the systems neuroscience of meal size control |
| Q43182574 | Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist |
| Q37040179 | Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4 |
| Q33940826 | Lipid-induced peroxidation in the intestine is involved in glucose homeostasis imbalance in mice |
| Q88732200 | Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons |
| Q92140921 | Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy |
| Q34068305 | Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers |
| Q38589032 | Mechanisms for the cardiovascular effects of glucagon-like peptide-1. |
| Q36800422 | Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling |
| Q57818654 | Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1) |
| Q37635255 | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. |
| Q37828337 | Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies |
| Q34060153 | Multiphoton microscopy applied for real-time intravital imaging of bacterial infections in vivo |
| Q30392753 | Negative Energy Balance Blocks Neural and Behavioral Responses to Acute Stress by "Silencing" Central Glucagon-Like Peptide 1 Signaling in Rats |
| Q27005992 | Neural control of energy balance: translating circuits to therapies |
| Q26749189 | Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist |
| Q33717424 | Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications |
| Q30412673 | Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect |
| Q40036350 | New ways in which GLP-1 can regulate glucose homeostasis |
| Q51478679 | Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. |
| Q46191665 | No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects |
| Q28240764 | Obesity wars: molecular progress confronts an expanding epidemic |
| Q48491427 | Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens |
| Q36339320 | PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. |
| Q35640531 | Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. |
| Q42626371 | Peptide and lipid modulation of glutamatergic afferent synaptic transmission in the solitary tract nucleus |
| Q36753785 | Peripheral tissue-brain interactions in the regulation of food intake |
| Q28076059 | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association |
| Q53074520 | Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs. |
| Q41809232 | Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats |
| Q42635500 | Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment |
| Q34410188 | Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity |
| Q33521451 | Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists |
| Q34981138 | Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem |
| Q57045579 | Preproglucagon Neurons in the Nucleus of the Solitary Tract are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food |
| Q34468359 | Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells |
| Q56930606 | Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults |
| Q38057350 | Review article: a comparison of glucagon-like peptides 1 and 2. |
| Q46573672 | Role of brain prostanoids in glucagon-like peptide-1-induced central activation of sympatho-adrenomedullary outflow in rats. |
| Q38533970 | Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocortical facilitation following chronic stress |
| Q37185214 | Role of central glucagon-like peptide-1 in stress regulation |
| Q36906311 | Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing |
| Q34382571 | Role of glucocorticoids in tuning hindbrain stress integration |
| Q56771767 | Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy |
| Q37708356 | Role of the glucagon-like-peptide-1 receptor in the control of energy balance |
| Q27000617 | Roux-en-Y gastric bypass: effects on feeding behavior and underlying mechanisms |
| Q37429747 | SF-1 expression in the hypothalamus is required for beneficial metabolic effects of exercise |
| Q41069307 | Serotonergic modulation of the activity of GLP-1 producing neurons in the nucleus of the solitary tract in mouse |
| Q38610870 | Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. |
| Q89472784 | Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats |
| Q33925948 | Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury |
| Q36721264 | Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium |
| Q34990224 | Spinally projecting preproglucagon axons preferentially innervate sympathetic preganglionic neurons |
| Q34355984 | Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium |
| Q37699068 | Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. |
| Q64118590 | The Discovery and Development of Liraglutide and Semaglutide |
| Q48052616 | The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice |
| Q30596646 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss |
| Q46906226 | The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice |
| Q36368998 | The cardiovascular effects of GLP-1 receptor agonists |
| Q37701737 | The diabetic cardiomyopathy |
| Q37980019 | The effect of glucagon-like peptide 1 on cardiovascular risk |
| Q36521217 | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
| Q51381364 | The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. |
| Q38146179 | The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q34970647 | The need to feed: homeostatic and hedonic control of eating |
| Q37442573 | The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake |
| Q28077787 | The physiological role of the brain GLP-1 system in stress |
| Q46161355 | The role of incretins in cardiovascular control |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q33634303 | The thyrotropin-releasing hormone gene is regulated by thyroid hormone at the level of transcription in vivo |
| Q35108463 | Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice |
| Q48157783 | Transient receptor potential vanilloid 1 antagonist, capsazepine, improves survival in a rat hemorrhagic shock model |
| Q39501242 | Transplantation of PC1/3-Expressing alpha-cells improves glucose handling and cold tolerance in leptin-resistant mice |
| Q39145953 | Uncertainties around incretin-based therapies: A literature review |
| Q39260864 | Understanding the cardiovascular effects of incretin. |
| Q38006504 | Update on incretin hormones |
| Q64978351 | Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. |
| Q47347620 | Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. |
| Q40165507 | Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y. |
| Q54522495 | [Cardiovascular effects of incretin-based therapies]. |
| Q84219888 | [Incretins: do they exert cardiovascular effects?] |
Search more.